New method for identifying proteins should have “a major impact on the development of new biologics,” U of T researcher says
Biologics are a type of drug that results from the high-tech manipulation of our own proteins, as opposed to more traditional drugs built from synthetic chemicals. Because of their success so far, scientists are racing to create new biologics – and now, a U of T researcher has developed a way to make that process more powerful.
Philip M. Kim, an associate professor in U of T’s Donnelly Centre for Cellular and Biomolecular Research, combined high-tech computer simulation and high-throughput laboratory experiments to create what he hopes will be the most effective way to discover the proteins that are key to new biologics. His research was published online in the journal Science Advances on July 20, 2016.
“A large fraction of new therapeutics these days involve engineered proteins that latch onto a drug target, for instance on a cancer cell,” says Kim, also of the departments of molecular genetics and computer science. “Finding a protein that effectively binds to a target can feel like looking for a needle in a haystack.
“Our method should open up new opportunities to find those key proteins – and make a major impact on the development of new biologics.”
Under the traditional approach to developing a biologic, researchers identify a protein of interest and then test billions of variants, either randomly generated or from a natural source, hoping to find an effective binder. But these methods allow very little control over where and how the protein performs this crucial function on its target – a major factor in its effectiveness.
Kim and his team took a different approach. They used a computer to simulate the binding process, and then designed proteins that would work on the target. This type of theoretical approach has been in development for several decades, but is still not effective enough. So Kim combined the best of both methods. Instead of randomly creating massive libraries of variants, as with the traditional approach, he used computer modelling to generate a smaller, but intelligently designed repertoire of variants. Designing each variant allows for the tight control of all its properties, in contrast to conventional approaches.
“We showed that this method gives you binders that are somewhat stronger than what you get with the conventional approach,” says Kim. “The much smaller library also solves many technical problems, and we can screen for new, previously unscreenable, targets. It’s a very exciting time for cancer research, and for biologics.”
For Kim, the next step is to produce proteins that are important to certain types of cancer, but have not been screened before due to the difficulty producing them.
Learn more: A more powerful way to develop therapeutics?
The Latest on: Biologics
via Google News
The Latest on: Biologics
- Allergan, Molecular Partners receive complete response letter from US FDA on biologics license application for Abicipar pegolon June 26, 2020 at 11:35 pm
has issued a Complete Response Letter to the Biologics License Application (BLA) for Abicipar pegol, a novel, investigational DARPin therapy for patients with neovascular (wet) age-related macular ...
- Using Disease Activity Measures to Guide Tapering and Compare Biologics to Treat RAon June 26, 2020 at 11:25 am
While biologics may have improved outcomes in rheumatoid arthritis (RA), they also have higher costs and adverse events, and patients are more likely to request dose reductions or drug holidays. While ...
- Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiencyon June 26, 2020 at 5:29 am
Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced the submission of a Biologics License ...
- BRIEF-Allergan, An Abbvie Company, And Molecular Partners Receive CRL From FDA On Biologics License Application For Abicipar Pegolon June 25, 2020 at 10:52 pm
ALLERGAN, AN ABBVIE COMPANY, AND MOLECULAR PARTNERS RECEIVE COMPLETE RESPONSE LETTER FROM FDA ON BIOLOGICS LICENSE APPLICATION FOR ABICIPAR PEGOL ...
- At 3.5% CAGR, Spine Biologics Market Size, Growth Research Analysis and Share to reach around US $2720 million by 2025on June 24, 2020 at 8:29 am
Selbyville, Delaware According to Market Study Report, Spine Biologics Market provides a comprehensive analysis ...
- Subcutaneous Biologics, Technologies and Drug Delivery Systems 2020-2030 - ResearchAndMarkets.comon June 23, 2020 at 3:24 am
The "Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030" report has been added to ResearchAndMarkets.com's offering. Biologics represent one of the fastest growing ...
- BRIEF-FDA Accepts Supplemental Biologics License Application For Botoxon June 22, 2020 at 11:03 am
FDA ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR BOTOX® (ONABOTULINUMTOXINA) FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY * ABBVIE INC - PRESCRIPTION ...
- Why Heat Biologics Stock Is Trading Higher Todayon June 22, 2020 at 7:54 am
Heat Biologics Inc (NASDAQ: HTBX) shares are trading higher on Monday after the company announced the first patient has been treated in its first-in-human clinical trial of ...
- MTF Biologics Wound Care Tissue Forms Now Accessible to Over 240 Million Americanson June 22, 2020 at 6:09 am
MTF Biologics, a global nonprofit organization that saves and heals lives through advancing tissue and organ donation, transplantation, and research, ...
- Heat Biologics Announces First Patient Treated in First-in-Human Clinical Trial of PTX-35on June 22, 2020 at 4:34 am
DURHAM, NC / ACCESSWIRE / June 22, 2020 / Heat Biologics, Inc. ("Heat") (HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, ...
via Bing News